AKT1 and familial pancreatic carcinoma: Our data indicate PROM2 enhanced gemcitabine chemoresistance in vitro and in vivo, which implies that PROM2 could serve as a biomarker for co-therapy of gemcitabine and Akt inhibitors in pancreatic cancer treatment.